Information Provided By:
Fly News Breaks for January 5, 2018
Jan 5, 2018 | 08:44 EDT
Roth Capital analyst Yasmeen Rahimi downgraded Ohr Pharmaceutical to Neutral from Buy after the company reported that Phase 3 MAKO trial did not meet its primary efficacy endpoint. Trials fail due to a drug's lack of efficacy, safety, or poor trial design and the MAKO trial's failure was due to efficacy, Rahimi tells investors.
News For OHRP From the Last 2 Days
There are no results for your query OHRP
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.